Find Clinical Trials

Search thousands of clinical trials by condition, location, and eligibility criteria

0
Total Trials
0
Trials Recruiting
0
Conditions Covered
0
Locations Worldwide
0
Sponsors
Clinical trial guides

Browse trials by condition

View all guides

Browse by location

Showing 12 of 4229 trials
Conditions Advanced or Metastatic Solid Tumors, Bre...
Phase PHASE1, PHASE2
Enrollment 120
Locations 14 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-09
Study Details Design, interventions, and primary outcomes

About This Study

This is a two-part, open-label, multicenter, dose escalation and dose expansion study designed to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PDx), and anti- tumor activity of ETX-19477, a novel reversible small molecule inhibitor of PARG.

Design

Study type: Interventional Phases: Phase1, Phase2 Allocation: Non Randomized Intervention model: Sequential Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Drug: ETX-19477 — Oral medication taken daily

Primary Outcomes

  • To characterize the safety and tolerability of ETX-19477, the maximum tolerated dose (MTD) and/or RP2D of ETX-19477 (6 months)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE1, PHASE2
Status: Recruiting
Start Date: 2024-05-13
Completion: 2026-12
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 120 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: 858 Therapeutics, Inc.
Principal Investigators:
  • Daniel McCormick (STUDY_DIRECTOR) - 858 Therapeutics, Inc.
Contact Information
Study Contact:
858 Therapeutics, Inc.
(858) 987-8380
dmccormick@8five8tx.com
Felipe Batalini, MD
Mayo Clinic
Michael Cecchini, MD
Yale University, Yale Cancer Center
Interventions
  • Drug: ETX-19477 — Oral medication taken daily
Study Locations (14 sites)
Mayo Clinic, Phoenix, Arizona 85054 United States
Yale University, Yale Cancer Center, New Haven, Connecticut 06510 United States
Mayo Clinic, Jacksonville, Florida 32224 United States
University of Chicago Medical Center, Chicago, Illinois 60637 United States
Massachusetts General Hospital, Boston, Massachusetts 02114 United States
Mayo Clinic, Rochester, Minnesota 55905 United States
Laura & Isaac Perlmutter Cancer Center at NYU Langone Health, New York, New York 10016 United States
Memorial Sloan Kettering Cancer Center, New York, New York 10065 United States
Stefanie Spielman Comprehensive Breast Center, Columbus, Ohio 43212 United States
Thomas Jefferson University, Sidney Kimmel Comprehensive Cancer Center, Philadelphia, Pennsylvania 19107 United States
Eligibility Criteria
Inclusion Criteria: * Males and females of age ≥ 18 years at the time of signing the informed consent document. * Histologically or cytologically confirmed advanced (incurable recurrent, unresectable, or metastatic) solid cancer, excluding primary central nervous system (CNS) tumors. * Any solid tumor malignancy, excluding primary CNS tumors, with progression on or after or intolerance to most recent systemic therapy. Preferential enrollment consideration will be made for patients with known BRCA2 mutations resulting in loss of function. * Measurable disease per RECIST v1.1. * ECOG performance status 0-1. * Progression on or after or intolerance to most recent systemic therapy. Prior treatment in the recurrent/metastatic setting; patients must have received approved standard therapy that is available to the patient that is known to confer clinical benefit, unless this therapy is contraindicated, intolerable to the patient, or is declined by the patient. * No investigational agent within 3 weeks or 5 half-lives (whichever is shorter; minimum of 2 weeks) prior to first dose of study drug. * Life expectancy of at least 3 months. Exclusion Criteria: * Receiving continuous corticosteroids at prednisone-equivalent dose of \>10 mg/day. Chronic systemic corticosteroid therapy for physiologic replacement (≤10 mg/day of prednisone equivalents) and the use of non-systemic corticosteroids (e.g., inhaled, topical, intra-nasal, intra-articular, or ophthalmic) are permitted. * Definitive radiotherapy within 6 weeks and palliative radiation within 2 weeks prior to the first dose of study drug. * Symptomatic untreated or progressing brain metastases. Stable, treated brain metastases are allowed if no evidence of radiologic or clinical progression or increasing corticosteroid use for at least 4 weeks. * Impairment of gastrointestinal (GI) function or GI disease that may significantly alter the absorption of ETX-19477 and no history of bowel obstruction within 6 months and/or peritoneal fluid drainage within 8 weeks prior to the first dose of study drug. * Known symptomatic and radiologically progressing or leptomeningeal disease (LMD). If LMD has been reported radiographically on baseline magnetic resonance imaging (MRI), but is not suspected clinically by the Investigator, the patient must be free of neurological symptoms of LMD. * Resting ECG with QT interval calculated using the Fridericia's formula (QTcF) \>470 msec on 2 or more timepoints within a 24-hour period, or history or family history of congenital long QT syndrome, or taking concomitant medications that are known to prolong the QT/QTc interval, or history of additional risk factors for torsades de pointes (Tdp). * History of myocardial infarction or unstable angina within 6 months prior to enrollment, or clinically significant cardiac disease, such as ventricular arrhythmia requiring therapy, uncontrolled hypertension, clinically significant uncontrolled arrhythmias, or any history of symptomatic congestive heart failure. * Known active or chronic infection (viral, bacterial, or fungal), including tuberculosis, hepatitis B, hepatitis C, or AIDS-related illness. Controlled infections, including HIV and "cured" hepatitis C (no active fever, no evidence of systemic inflammatory response syndrome) that are stable with undetectable viral load on antiviral treatment are not exclusionary. * Acute or chronic uncontrolled renal disease, pancreatitis, or liver disease (with exception of patients with Gilbert's Syndrome, asymptomatic gallstones, liver metastases, or stable chronic liver disease per Investigator assessment). * Known other previous/current malignancy requiring treatment within ≤2 years except for limited disease treated with curative intent, such as carcinoma in situ, squamous or basal cell skin carcinoma, or superficial bladder carcinoma and not requiring ongoing chemotherapy. * Patients receiving proton pump inhibitors (PPIs), strong cytochrome P450 (CYP)3A inhibitors and inducers, or P-glycoprotein (P-gp) inhibitors. Patients should not receive PPIs within 7 days prior to first dose of study drug. Strong CYP3A inducers or inhibitors or strong P-gp inhibitors should not be given within 6 half-lives prior to first dose of study drug. * Patients currently treated with therapeutic doses of warfarin sodium (Coumadin®) or any other coumarin-derivative anticoagulants
Conditions Triple Negative Breast Cancer
Phase EARLY_PHASE1
Enrollment 20
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-09
Study Details Design, interventions, and primary outcomes

About This Study

This clinical study will investigate the utility of Fludeoxyglucose (18F) fluoromisonidazole (FMISO), in patients diagnosed with triple negative breast cancer (stage II-IV disease), to monitor and predict the effect of immunotherapy. This is a parallel imaging study to current treatment strategies and no clinical decisions or outcomes will be based on the imaging. If promising, this data will be used to design larger trials. A total of 20 patients will be recruited for this study. This trial will not designate the participant's treatment plan; they will be eligible based on their treatment plan designated from their oncologist.

Design

Study type: Interventional Phases: Early Phase1 Allocation: Intervention model: Single Group Primary purpose: Diagnostic Masking/blinding: None

Interventions / Regimen

  • Drug: [18F]FMISO-PET with contrast-enhanced MRI — Triple negative breast cancer patients that are planning to undergo immunotherapy and consent to this study will have 3 imaging visits. Imaging visit 1 will take place before the patients start immunotherapy. Imaging Visit 2 will take place after the patient completes the 1st cycle of immunotherapy and before they start their 2nd cycle. Imaging Visit 3 will take place when the patient completes the 2nd cycle of immunotherapy and before they start the 4th cycle.

Primary Outcomes

  • Baseline measure of PET standardized uptake value (SUV). (Baseline)
  • Baseline measure of apparent diffusion coefficient (ADC) in mm2/sec from MRI. (Baseline)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: EARLY_PHASE1
Status: Recruiting
Start Date: 2027-06
Completion: 2030-08
Eligibility
Age: 18 Years – 75 Years
Sex: FEMALE
Volunteers: false
Enrollment: 20 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: University of Alabama at Birmingham
Principal Investigators:
  • Janis O'Malley, MD (PRINCIPAL_INVESTIGATOR) - University of Alabama at Birmingham
Contact Information
Study Contact:
Sebastian Eady
205-996-2636
smeady@uabmc.edu
Sebastian Eady
205-966-2636
smeady@uabmc.edu
UAB
Interventions
  • Drug: [18F]FMISO-PET with contrast-enhanced MRI — Triple negative breast cancer patients that are planning to undergo immunotherapy and consent to this study will have 3 imaging visits. Imaging visit 1 will take place before the patients start immunotherapy. Imaging Visit 2 will take place after the patient completes the 1st cycle of immunotherapy and before they start their 2nd cycle. Imaging Visit 3 will take place when the patient completes the 2nd cycle of immunotherapy and before they start the 4th cycle.
Study Locations (1 sites)
UAB, Birmingham, Alabama 35249 United States
Eligibility Criteria
Inclusion Criteria: 1. Patients must be ≥ 18 years old and ≤ 75 years old 2. Triple negative breast cancer (TNBC) patients (biopsy-proven) stage II-IV eligible 3. \>50%Programmed death-ligand 1 (PD-L1) positive 4. Eligible for immunotherapy who are naïve to beginning any immunotherapy treatment 5. May not be pregnant or breastfeeding 6. Subjects must be willing to sign consent 7. Adequate creatinine clearance per institutional guidelines and within 30 days 8. Estimated life expectancy of greater than one year 9. Patients must have one lesion with RECIST measurable disease (greater than 1 cm in diameter, measured from diagnostic breast MRI or staging CT) Exclusion Criteria: 1. Inability to provide informed consent 2. Weight over 350 lbs., due to the scanner bore size 3. Lactating, known or suspected pregnancy. Women with child-bearing potential must a have a negative serum Human chorionic gonadotropin (β-hCG) pregnancy test within 48 hours or a negative urine β-hCG pregnancy test within 24 hours of each PET imaging study. 4. Contraindication for MRI study (e.g. non-removable metal implants or certain tattoos) 5. Unable to lie still on the imaging table for one (1) hour 6. contraindication for gadolinium-based contrast agent, ProHance (gadoteridol) 7. Have received immunotherapy in the neoadjuvant or adjuvant setting
Conditions Breast Cancer
Phase NA
Enrollment 84
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-09
Study Details Design, interventions, and primary outcomes

About This Study

The present study aims to find a perioperative analgesic method that provides sufficient analgesia while reducing immune compromise in cancer surgery. This study is to investigate the analgesic effect and safety of Maxigesic inj. (a combination of acetaminophen 1000 mg and ibuprofen 300 mg), which is added to opioid-based IV-PCA in patients undergoing breast cancer surgery.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Other Masking/blinding: Triple

Interventions / Regimen

  • Drug: Maxigesic — For postoperative analgesia, 50 mcg of fentanyl was administered 15 minutes before the end of surgery, and IV-PCA (fentanyl 1.0 mcg/kg, ramosetron 0.3 mg, total 250cc, infusion rate 5cc/h, bolus 0.5 cc, lock-out time 15min) is started. Additionally, in the Maxigesic group, one vial of Maxigesic (acetaminophen 1000mg/ ibuprofen 300mg) is administered 15 minutes before the end of the surgery, and 2 vials of Maxigesic are added to the IV-PCA.
  • Drug: 0.9% saline solution — For postoperative analgesia, 50 mcg of fentanyl was administered 15 minutes before the end of surgery, and IV-PCA (fentanyl 1.0 mcg/kg, ramosetron 0.3 mg, total 250cc, infusion rate 5cc/h, bolus 0.5 cc, lock-out time 15min) is started. Additionally, in the control group, the same amount of 0.9% saline solution with Maxigesic is administered.

Primary Outcomes

  • Analgesic effect of Maxigesic (postoperative 30 minutes/ 6 hours/ 24 hours/ 48 hours)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2023-12-28
Completion: 2025-12-26
Eligibility
Age: 20 Years – 70 Years
Sex: FEMALE
Volunteers: false
Enrollment: 84 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Yonsei University
Contact Information
Study Contact:
Jin Sun Cho
82-2-2228-2419
chjs0214@yuhs.ac
Jin Sun Cho
Department of Anesthesiology and Pain Medicine, Yonsei University College of Medicine
Interventions
  • Drug: Maxigesic — For postoperative analgesia, 50 mcg of fentanyl was administered 15 minutes before the end of surgery, and IV-PCA (fentanyl 1.0 mcg/kg, ramosetron 0.3 mg, total 250cc, infusion rate 5cc/h, bolus 0.5 cc, lock-out time 15min) is started. Additionally, in the Maxigesic group, one vial of Maxigesic (acetaminophen 1000mg/ ibuprofen 300mg) is administered 15 minutes before the end of the surgery, and 2 vials of Maxigesic are added to the IV-PCA.
  • Drug: 0.9% saline solution — For postoperative analgesia, 50 mcg of fentanyl was administered 15 minutes before the end of surgery, and IV-PCA (fentanyl 1.0 mcg/kg, ramosetron 0.3 mg, total 250cc, infusion rate 5cc/h, bolus 0.5 cc, lock-out time 15min) is started. Additionally, in the control group, the same amount of 0.9% saline solution with Maxigesic is administered.
Study Locations (1 sites)
Department of Anesthesiology and Pain Medicine, Yonsei University College of Medicine, Seoul, South Korea
Eligibility Criteria
Inclusion Criteria: * Patient aged 20 to 70 years with ASA classification 1 to 3 undergoing breast cancer surgery (cancer resection or reconstruction) Exclusion Criteria: * ASA classification 4/ allergy to acetaminophen, NSAIDs, opioid/ severe liver or renal dysfunction/ pregnancy
Conditions Breast Cancer, Early-Stage Invasive Brea...
Phase Not Applicable
Enrollment 500
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-09
Study Details Design, interventions, and primary outcomes

About This Study

This prospective, multicenter observational cohort study evaluates long-term outcomes in patients with early-stage invasive breast cancer who undergo breast-conserving surgery without sentinel lymph node biopsy or other axillary surgery and subsequently receive adjuvant radiotherapy. The study will evaluate recurrence, survival, radiotherapy-related toxicities, and quality of life. Radiotherapy will be delivered according to routine clinical practice at each participating institution without protocol-mandated treatment assignment. Detailed radiotherapy characteristics, including treatment volume, technique, dose and fractionation, tumor-bed boost, and radiation dose to axillary lymph node levels I-III, will be prospectively collected to evaluate their associations with clinical outcomes.

Design

Study type: Observational Observational model: Cohort Time perspective: Prospective

Interventions / Regimen

  • Radiation: Adjuvant Breast Radiotherapy — Adjuvant radiotherapy is delivered after breast-conserving surgery according to routine clinical practice at each participating institution. Radiotherapy may include whole-breast irradiation or partial-breast irradiation, with treatment technique, dose, fractionation, and tumor-bed boost determined by the treating physician. The study does not assign or mandate a specific radiotherapy regimen.

Primary Outcomes

  • 5-Year Recurrence-Free Survival Rate (From study enrollment to 5 years)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2026-08-06
Completion: 2036-08-05
Eligibility
Age: 19 Years and older
Sex: FEMALE
Volunteers: false
Enrollment: 500 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Samsung Medical Center
Contact Information
Study Contact:
Haeyoung Kim
+82234102612
haeyoung0131.kim@samsung.com
Haeyoung Kim
+82234102612
haeyoung0131.kim@samsung.com
Samsung Medical Center
Wonkyung Cho
wklove.cho@gmail.com
Samsung Medical Center
Interventions
  • Radiation: Adjuvant Breast Radiotherapy — Adjuvant radiotherapy is delivered after breast-conserving surgery according to routine clinical practice at each participating institution. Radiotherapy may include whole-breast irradiation or partial-breast irradiation, with treatment technique, dose, fractionation, and tumor-bed boost determined by the treating physician. The study does not assign or mandate a specific radiotherapy regimen.
Study Locations (1 sites)
Samsung Medical Center, Seoul, 05649 South Korea
Eligibility Criteria
Inclusion Criteria: * Female patients aged 19 years or older with histologically confirmed invasive breast cancer * Patients who have undergone breast-conserving surgery with curative intent * Patients who did not undergo axillary lymph node surgery, including sentinel lymph node biopsy, at the time of breast cancer surgery * No evidence of distant metastasis on clinical and imaging evaluation before surgery * Planned to receive adjuvant radiotherapy after breast-conserving surgery * Ability and willingness to provide written informed consent before study participation Exclusion Criteria: * Patients initially diagnosed with breast carcinoma in situ before surgery who did not undergo sentinel lymph node biopsy but were subsequently found to have invasive breast cancer on final surgical pathology * Receipt of neoadjuvant systemic therapy before breast cancer surgery * History of a malignancy other than breast cancer within 5 years before study enrollment, except adequately treated non-melanoma skin cancer or carcinoma in situ other than breast carcinoma in situ * Recurrent breast cancer * Bilateral breast cancer or inflammatory breast cancer * Prior radiotherapy to the ipsilateral breast or chest region * Patients considered by the investigator to be unsuitable for study participation or long-term follow-up
Conditions Motor Function, Cognitive Function, Cont...
Phase PHASE4
Enrollment 2076
Locations 51 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-09
Study Details Design, interventions, and primary outcomes

About This Study

This study is a postmarketing requirement jointly carried out by four NDA holders (Bayer AG, Bracco, GE Healthcare and Guerbet) and the CRO IQVIA. The study aims to create detailed images of the organs and tissue of the human body during x-ray, CT-scan or MRI investigations, doctors are using contrast media (a kind of dye) which can be given to patients by injection into a blood vessel or by mouth. In this study researchers want to find out whether so called gadolinium-based contrast agents (GBCAs) have an effect on body movement and mental skills when given to participants multiple times within 5 years. The study plans to enroll about 2076 participants suffering from a condition for which they are likely to have at least annually a MRI or another imaging examinations. Only adults up to 65 years will be considered to join this study. During the study duration of 5 years participants will receive annually a MRI or other imaging tests (such as CT-scan, x-ray) and will visit the study doctor at least 7 times for physical examinations, laboratory investigations and tests on body movement and mental skills.

Design

Study type: Interventional Phases: Phase4 Allocation: Non Randomized Intervention model: Parallel Primary purpose: Other Masking/blinding: None

Interventions / Regimen

  • Procedure: Motor Tests — To assess motor function annually
  • Procedure: Cognitive Tests — To assess cognitive function annually
  • Procedure: Unenhanced-MRI of the brain — The UE-MRI of the brain will be performed at baseline and at the year 5 visit in order to exclude presence of a significant MRI abnormality
  • Procedure: Gadolinium Measurements — Blood samples and spontaneous urine specimens will be collected through the course of the study to measure Gd concentration
  • Drug: Gadoxetate disodium — Administered as defined by the treating physician as part of routine clinical practice
  • Drug: Gadobenate dimeglumine — Administered as defined by the treating physician as part of routine clinical practice
  • Drug: Gadodiamide — Administered as defined by the treating physician as part of routine clinical practice
  • Drug: Gadoterate meglumine — Administered as defined by the treating physician as part of routine clinical practice

Primary Outcomes

  • Change of motor function from baseline to year 5 in comparison to a matched non-GBCA-exposed control group (At baseline, year 5)
  • Change in cognitive function from baseline to year 5 in comparison to a matched non-GBCA-exposed control group (At baseline, year 5)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE4
Status: Recruiting
Start Date: 2021-03-24
Completion: 2028-12-31
Eligibility
Age: 18 Years – 64 Years
Sex: ALL
Volunteers: false
Enrollment: 2076 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Guerbet
Collaborators: Bayer AG (Sponsor), Bracco (Sponsor), GEHC (Sponsor)
Contact Information
Study Contact:
Nathalie LE FUR, PhD
+33649351166
nathalie.lefur@guerbet.com
Frantz HEBERT
+33680249334
frantz.hebert@guerbet.com
4804254194
comrkorn@imagingendpoints.com
Scottsdale Medical Imaging, LLC
Interventions
  • Procedure: Motor Tests — To assess motor function annually
  • Procedure: Cognitive Tests — To assess cognitive function annually
  • Procedure: Unenhanced-MRI of the brain — The UE-MRI of the brain will be performed at baseline and at the year 5 visit in order to exclude presence of a significant MRI abnormality
  • Procedure: Gadolinium Measurements — Blood samples and spontaneous urine specimens will be collected through the course of the study to measure Gd concentration
  • Drug: Gadoxetate disodium — Administered as defined by the treating physician as part of routine clinical practice
Study Locations (51 sites)
Scottsdale Medical Imaging, LLC, Scottsdale, Arizona 85260 United States
Yale University School of Medicine, New Haven, Connecticut 06520 United States
University of Chicago Medical Center, Chicago, Illinois 60637 United States
Methodist Medical Center of Illinois, Peoria, Illinois 61637 United States
Massachussets General Hospital, Boston, Massachusetts 02114 United States
Boston University Medical Center, Boston, Massachusetts 02118 United States
Beth Israel Deaconess Medical Center, Boston, Massachusetts 02215 United States
ActivMed Practices & Research, Inc., Methuen, Massachusetts 01844 United States
University of Massachusetts Memorial Medical Center, Worcester, Massachusetts 01655 United States
Department of Radiology, St Louis, Missouri 63110 United States
Eligibility Criteria
Inclusion Criteria: * Participant must be neurologically normal, defined as free of unstable neurologic and psychiatric disease as confirmed by a normal neurologic examination at screening * Participant (GBCA-exposed or controls) agrees to undergo unenhanced magnetic resonance imaging (UE-MRI) of the brain at enrollment and at the end of the observation period (5 years) * Participants should have at least 1 of the following indications: a) Medium to high risk for breast cancer or dense breasts undergoing breast cancer screening with MRI, b) Elevated prostate-specific antigen (PSA) and under active diagnostic surveillance for prostate cancer, c) Chronic liver disease (eg, liver cirrhosis limited to Child class A, post-hepatitis chronic hepatopathy, or primary sclerosing cholangitis) for surveillance of hepatocellular carcinoma development, d) Low-grade colorectal cancer or neuroendocrine tumor undergoing screening for liver metastases or e) Branch-duct intraductal papillary mucinous neoplasm (IPMN) of the pancreas (maximum size ≤2 cm) undergoing imaging surveillance. In addition, for participants in the GBCA Arms only: * Each participant should be likely to undergo ≥5 GBCA-enhanced MR examinations with the same GBCA at least annually throughout the 5-year study duration * Prospective participants with up to 3 well documented GBCA administrations prior to study screening are acceptable, provided that the imaging was performed with the same GBCA as the one to be prospectively used in the study. If the GBCA used cannot be identified, he/she cannot be enrolled. For the Control Arm: * Participants who never had and are not likely to receive any GBCA injection during the course of the study * Each control participant must be willing to undergo UE-MRI of the brain at baseline and at Year 5. In Years 1 to 4, the control participants will undergo their clinically indicated UE-MRIs, computed tomography (CT), ultrasound, or X-ray procedures Exclusion Criteria: * As evidenced by history or determined in the neurologic exam at screening, concurrent neurological and/or psychiatric disease (or treatments) that could influence the results of the study's motor and cognitive tests (e.g. Cerebrovascular disease, Multiple sclerosis, Neurodegenerative disease, Malignant disease other than listed in indications, Carcinoid tumors, Epilepsy, Prior neurosurgery, Psychotic disorders or any prior psychotic episode not otherwise specified - any documented prior history of chronic schizophrenia, Remittent or current medically confirmed major depressive disorder or bipolar disorder, History of long-term major depression or bipolar affective disorder with an active episode in the past 2 to 5 years, Neurodevelopmental disorders (eg, trisomy 21), Uncontrolled severe migraine, Uncontrolled or controlled anxiety or depression within 6 months before enrollment, Screening scores of ≤24 on the MMSE and/or ≥11 on the Hospital Anxiety and Depression Scale (HADS)). * Prior, planned, or ongoing chemotherapy or brain irradiation * Use of concomitant medication(s) affecting neuro-cognitive or motor function * Substance or alcohol abuse as determined by the investigator * Alcoholic cirrhosis * Renal disease, defined as estimated glomerular filtration rate (eGFR) \< 60 mL/min/1.73 m2 * History of environmental/occupational/other exposure to one or more chemicals that may affect cognitive and/or motor function, including, but not limited to, heavy metals (arsenic \[As\], cadmium \[Cd\], lead \[Pb\], manganese \[Mn\], and mercury \[Hg\]), pesticides, solvents, or carbon monoxide. * Clinical indications requiring \>1 contrast enhanced magnetic resonance imaging (CE-MRI) every 6 months * Pregnant or nursing (lactating) women * Presence of any metal-containing joint implants/prostheses In addition, for participants in either of the GBCA Arms only: \- Receipt of a GBCA or generic prior to study entry other than the specific GBCA to be administered during the course of the study. For participants in the Control Arm only: * Participants with any previous exposure to a GBCA. * Participants with any contraindication to UE-MRI examinations.
Conditions Breast Cancer, HER2-negative Breast Canc...
Phase PHASE2
Enrollment 176
Locations 7 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-09
Study Details Design, interventions, and primary outcomes

About This Study

The purpose of this study is to look at how effective neoadjuvant (before surgery) endocrine therapy (NET) is in participants with invasive lobular carcinoma (ILC) who have breast-conserving surgery (BCS). The main purpose of the study is to see if NET reduces the chance of having cancer cells at the edges of tissue removed during surgery (positive margins).

Design

Study type: Interventional Phases: Phase2 Allocation: Intervention model: Single Group Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Drug: Neoadjuvant endocrine therapy — The endocrine therapy used for the NET in this study will be anastrozole, letrozole, exemestane, or tamoxifen.

Primary Outcomes

  • Rate of positive surgical margins after breast cancer surgery (up to 3 months)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE2
Status: Recruiting
Start Date: 2026-03-13
Completion: 2030-03-13
Eligibility
Age: 50 Years and older
Sex: FEMALE
Volunteers: false
Enrollment: 176 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Memorial Sloan Kettering Cancer Center
Principal Investigators:
  • Anita SKCCSC(P Mamtani, MD (PRINCIPAL_INVESTIGATOR) - Memorial Sloan Kettering Cancer Center
Contact Information
Study Contact:
Anita Mamtani, MD
646-888-6864
mamtana1@mskcc.org
George Plitas, MD
646-888-5368
PlitasG@mskcc.org
Anita Mamtani, MD
646-888-6864
Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities)
Interventions
  • Drug: Neoadjuvant endocrine therapy — The endocrine therapy used for the NET in this study will be anastrozole, letrozole, exemestane, or tamoxifen.
Study Locations (7 sites)
Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities), Basking Ridge, New Jersey 07920 United States
Memorial Sloan Kettering Monmouth (Limited Protocol Activities), Middletown, New Jersey 07748 United States
Memorial Sloan Kettering Bergen (Limited Protocol Activities), Montvale, New Jersey 07645 United States
Memorial Sloan Kettering Suffolk - Commack (Limited Protocol Activities), Commack, New York 11725 United States
Memorial Sloan Kettering Westchester (Limited Protocol Activities), Harrison, New York 10604 United States
Memorial Sloan Kettering Cancer Center (All Protocol Activities), New York, New York 10065 United States
Memorial Sloan Kettering Nassau (Limited Protocol Activities), Uniondale, New York 11553 United States
Eligibility Criteria
Inclusion Criteria: * Written informed consent by participant or legally authorized representative * Postmenopausal women aged ≥50 years with biopsy-proven cT2-T3 N0-1 ILC who opt to undergo and are medically fit to undergo BCS at enrollment. * Tumors of the ER+/HER2- subtype, defined as: 1. ER+: Positive for ER staining as indicated by ≥10% immunoreactive tumor nuclei. 2. HER2-: Immunohistochemistry assay demonstrating no or faint staining in ≤10% of tumor cells (IHC 0 or 1+) or negative by dual probe in situ hybridization assay. Exclusion Criteria: * Patients with prior ipsilateral breast cancer. * Patients with advanced regional disease (cN2/cN3) or stage 4 disease. * Patients who would benefit from neoadjuvant chemotherapy, per the treating medical oncologist. * Patients who are not candidates for definitive breast surgery (inoperable or stage 4 disease). * Patients with gadolinium allergy, precluding the use of breast MRI.
Conditions Prostate Cancer, Breast Cancer
Phase NA
Enrollment 124
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-09
Study Details Design, interventions, and primary outcomes

About This Study

Radiation therapy (RT) is a key component in the treatment of breast and prostate cancer. However, patients may experience significant side effects. Patients can accurately self-report side effects from RT and these patient-reported outcomes (PROs) can direct communication between patient and healthcare provider (HCP), and facilitate joint decision making. Patients state that using mobile phone applications (apps) to collect PROs (mPROs) is easily incorporated into their daily routines, allowing them to engage at a time and pace that suits them. When mPRO collection is combined with remote symptom monitoring by HCPs, these systems result in improvements in symptom control and quality of life. Currently, patients receiving RT are seen by a Radiation Oncologist once per week during RT and once every few months after RT has finished. Recent evaluations indicate that patients and physicians consider the number of visits to be too frequent during RT, and too infrequent immediately after RT. This research will use weekly mPROs (remotely monitored by RT HCP) to determine if a patient needs (or wants) to be seen by a RT HCP during and/or immediately after RT. Using mPROs to optimize RT patient assessment processes will ensure patients are seen if and when required. For a patient, this could result in reduced time and costs at the hospital. For the physician, resources could be re-allocated to improve access to RT services. Using mPROs after RT has the potential for earlier treatment of side effects, which has been linked to improved survival and quality of life.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Supportive Care Masking/blinding: Single

Interventions / Regimen

  • Other: Remote monitoring PROs — Attendance at RT review appointments triaged based on remotely monitored PROs

Primary Outcomes

  • Remote monitoring efficiency (At the end of radiation (average 5 weeks), and 12 weeks after completion of radiation)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2024-04-09
Completion: 2025-10-31
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 124 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: University Health Network, Toronto
Contact Information
Study Contact:
Tara Rosewall, PhD
416 946 2000
tara.rosewall@rmp.uhn
Tara Rosewall
4162098269
tara.rosewall@rmp.uhn.ca
Princess Margaret Cancer Centre
Winnie Li
4169462000
winnie.li@uhn.ca
Princess Margaret Cancer Centre
Interventions
  • Other: Remote monitoring PROs — Attendance at RT review appointments triaged based on remotely monitored PROs
Study Locations (1 sites)
Princess Margaret Cancer Centre, Toronto, Ontario M5G 2J9 Canada
Eligibility Criteria
Inclusion Criteria: * Clinical diagnosis of breast or prostate cancer * About to receive a course of radical or adjuvant radiation therapy as an outpatient at Princess Margaret Cancer Centre * Able to enter PRO responses into the mobile app in English or French Exclusion Criteria: * Significant comorbidities that would render the patient not suitable for remote monitoring
Conditions Menopause, Obesity and Overweight
Phase NA
Enrollment 84
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-09
Study Details Design, interventions, and primary outcomes

About This Study

This study is aimed at women currently going through menopause, either as part of the natural process (physiological menopause), or following hormonal treatment for breast cancer. There are several ways of slowing the weight gain frequently encountered in this situation, reducing the intensity of menopause-related symptoms and improving quality of life in this context. In this trial, the investigators examine the efficacy and possible adverse effects of intermittent fasting compared with a control intervention. Participation lasts 14 weeks, with an optional 12-month follow-up. Study participants are randomly assigned to either the intervention group or the control group. In the intervention group, study participants fast for 16 hours per day and eat over a period of 8 hours (intermittent fasting often called time-restricted eating \[TRE\] 16h/8h). In the control group, the usual eating pattern is continued for 12 weeks. The main objective of the study is to evaluate the efficacy of TRE in terms of weight and fat loss, improvement in metabolic profile, menopausal symptoms and bone health. In addition, the study team closely monitors any adverse effects.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Behavioral: Time-Restricted Eating 16h/8h — Participants will be advised to eat only during a self-selected window of 8 hours over the 24-hour cycle, with a 1-hour allowance according to their daily routine.
  • Behavioral: Active Control — Participants will be advised to eat 2 to 3 meals every day according to their eating habits and social activities

Primary Outcomes

  • Changes in body weight (From randomization visit to close-out visit (12 weeks))
  • Changes in body fat mass (From randomization visit to close-out visit (12 weeks))
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2025-04-30
Completion: 2027-03-01
Eligibility
Age: 45 Years – 60 Years
Sex: FEMALE
Volunteers: false
Enrollment: 84 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: University Hospital, Geneva
Contact Information
Study Contact:
Tinh-Hai Collet, MD
+41-22-372 91 92
tinh-hai.collet@hug.ch
Céline Joris, BSc
celine.joris@hug.ch
Tinh-Hai Collet, MD
+41-22-372 91 92
tinh-hai.collet@hug.ch
Geneva University Hospitals
Interventions
  • Behavioral: Time-Restricted Eating 16h/8h — Participants will be advised to eat only during a self-selected window of 8 hours over the 24-hour cycle, with a 1-hour allowance according to their daily routine.
  • Behavioral: Active Control — Participants will be advised to eat 2 to 3 meals every day according to their eating habits and social activities
Study Locations (1 sites)
Geneva University Hospitals, Geneva, Canton of Geneva 1211 Switzerland
Eligibility Criteria
Inclusion Criteria: * Women with confirmed physiological menopause without current anti-cancer treatment (group A), or women with menopausal symptoms in the context of aromatase inhibitors used as adjuvant therapy for hormone-sensitive non-metastatic breast cancers regardless of physiological menopause before the cancer diagnosis (group B) * Age 40-65 years * Body mass index 25-40 kg/m2 * Stable weight (± 2 kg) over the previous month * Eating window ≥ 12 hours (self-reported and measured during the run-in phase) * Able to give informed consent and follow the study procedures for the entire duration * Confident use of a smartphone and able to take regular pictures of food/drinks Exclusion Criteria: * On a hypocaloric restrictive diet, intermittent fasting or in a weight management program over the previous month * Previous bariatric surgery or planned during the study * Active eating disorder(s) or major mental illness at inclusion * Psychoactive treatment with recent or planned changes of drug compound or dosage * Treatments affecting body weight (e.g. glucocorticoids, GLP-1 receptor analogues) * Diabetes with hypoglycemic drug(s) will be excluded, however those with prediabetes (as defined by the American Diabetes Association) or diabetes with no risk of hypoglycemia (i.e. treated with non-hypoglycemic drugs or without medication) will be included * Active metabolic bone diseases (e.g. Paget disease, osteomalacia), however women with osteoporosis will be included * Shift work comprising night shifts (working between 11pm and 6am) over the previous 2 weeks or planned during the study * Travel/trip to a different time zone (≥ 2-hour time difference) over the previous 2 weeks or planned during the study * Enrolled in another interventional clinical trial (medication, surgery, medical device) over the previous 2 weeks or planned during the study
Conditions Breast Cancer
Phase PHASE2
Enrollment 22
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-09
Study Details Design, interventions, and primary outcomes

About This Study

The purpose of this research is to look at the safety and effectiveness of a HER2-targeted therapy neratinib when given with capecitabine, a chemotherapy, for breast cancer patients with brain metastases whose tumors were HER2-negative by standard tests but showed abnormal HER2 activity based on the CELsignia results.

Design

Study type: Interventional Phases: Phase2 Allocation: Intervention model: Single Group Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Drug: Capecitabine and Neratinib. — Neratinib 240 mg PO QD Daily On-going Capecitabine 750 mg/m2 PO bid Days 1-14, 7 days off On-going

Primary Outcomes

  • overall survival (24 months)
  • CNS progression free survival (24 months)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE2
Status: Recruiting
Start Date: 2022-09-23
Completion: 2027-09-01
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 22 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: University of Rochester
Principal Investigators:
  • Ajay Dhakal (PRINCIPAL_INVESTIGATOR) - University of Rochester
Contact Information
Study Contact:
Jamie Littleton
(585) 273-1507
WCICTOResearch@URMC.Rochester.edu
Jamie Littleton
WCICTOResearch@URMC.Rochester.edu
University of Rochester
Interventions
  • Drug: Capecitabine and Neratinib. — Neratinib 240 mg PO QD Daily On-going Capecitabine 750 mg/m2 PO bid Days 1-14, 7 days off On-going
Study Locations (1 sites)
University of Rochester, Rochester, New York 14642 United States
Eligibility Criteria
Inclusion Criteria: * Subjects must meet all of the following criteria to be enrolled: * Male/Female * At least 18 years of age * Histologically confirmed HER2 negative breast cancer determined from the most recent tumor sample (primary or metastatic), as per the current American Society of Clinical Oncology and College of American Pathologists HER2 testing guidelines. * For ER positive breast cancer patients: prior treatment with a CDK4/6 inhibitor and endocrine therapy in required in the metastatic settings. If a patient has received a CDK4/6 inhibitor plus endocrine therapy in the adjuvant settings and the cancer recurred while on the CDK4/6 inhibitor or within 12 months of the end of CDK4/6 inhibitor treatment, then the patient will eligible without getting a CDK4/6 inhibitor and endocrine therapy in the metastatic setting. * For triple negative breast cancer patients: no specific prior anti-cancer treatment is required. * Have radiological evidence of one or more brain metastases. * Ability to obtain an MRI. * Has a radiological evidence of a measurable disease (per RECIST 1.1) outside of the brain which is accessible to a biopsy * Willing to undergo a research core biopsy of the tumor tissue * Considered to be medically fit for undergoing a biopsy * Subjects anticipated by the investigator to be a candidate for systemic therapy immediately or in the future. * Ability to understand the investigational nature of the study and sign the informed consent * Key Criteria for Step 1 Registration: * Abnormally active HER2 signaling as determined by the CELsignia test on the tumor tissue. * New or progressive brain metastases defined as any one of the following: * Untreated measurable lesions in patients who have received surgery and/or stereotactic radiosurgery (SRS) to one or more other lesions. * Residual or progressive lesions after surgery if asymptomatic. * Patients who have had prior whole-brain radiotherapy (WBRT) and/or SRS and then whose lesions have progressed by RANO-BM criteria or there are new lesions are eligible. Lesions treated with SRS may be eligible if there is unequivocal evidence of progression. * Patients who have not previously been treated with cranial radiation (e.g., WBRT or SRS) are eligible, but such patients must be asymptomatic and neurologically stable from their CNS metastases. * Measurable brain metastases with at least one lesion \> 5 mm in longest diameter AND is/are new or progressive lesion/s as defined by criterion B. * Ability to obtain MRI * No major surgery within 10 days prior to registration. Surgeries should be avoided any time after registration during the study treatment, but minor procedures like dental extractions and surgeries deemed important to maintain or improve patients' quality of life and are allowed. * A minimum of 14 days since the last dose of chemotherapy except for the optional pre-Step 1 capecitabine. If pre-step 1 optional capecitabine was administered, then a minimum of 7 days from the last dose of Capecitabine is required before registration. There is no limit on the number of previous chemotherapy regimens for eligibility. * A minimum of 7 days since the last dose of any hormonal therapy (no limit on the number of previous hormonal regimens for eligibility) except fulvestrant. A minimum of 28 days since the last dose of fulvestrant before registration. * A minimum of 21 days since the last dose of targeted therapy (e.g., a CDK4/6 inhibitor, PI3kinase inhibitors, etc.) * A minimum of 7 days since the last fraction of extracranial radiation and has recovered from any acute toxic effects of radiation therapy * A minimum of 30 days since the last dose of any investigational cancer treatment or any immunotherapy * ECOG performance status of 0 -2 * Left ventricular ejection fraction ≥ 50% at baseline * Prior treatment-related major organ toxicities recovered to ≤grade 1 * Adequate bone marrow, hepatic, renal, and coagulation function * Post-menopausal, surgically sterile, or willing to use a reliable form of contraception while on the study and for 180 days after discontinuing either study treatment. The patients that can father children are willing to use highly effective contraception for at least 90 days following last dose of either study treatment. * Ability to understand the investigational nature of the study and sign the informed consent Exclusion Criteria: * Subjects must NOT meet any of the following criteria to be enrolled: * Patients who have received capecitabine for the treatment of the current breast cancer in the metastatic setting * Patients who have received capecitabine only in the perioperative setting for the primary early-stage breast cancer AND the breast cancer recurred while taking capecitabine or within 180 days of the last dose of capecitabine therapy. * History of other malignancies other than the following: 1. adequately treated non-melanoma skin cancer, 2. curatively treated in-situ cancer of the cervix 3. other solid tumors which have been curatively treated AND no evidence of recurrence in the last 2 years. * Gastrointestinal tract disease resulting in an inability to absorb oral medication * Known hypersensitivity to the study drugs or their components * Pregnant or breast-feeding * Known or suspected leptomeningeal disease * Known bleeding or coagulation issues, subject taking anticoagulants or having bleeding diathesis that may significantly increase the risk of bleeding during the biopsy. If the subject is on anticoagulation, perioperative management of anticoagulation should be done per institutional practice. * Chronic and concomitant use of strong or moderate CYP3A4 inhibitors and strong or moderate CYP3A4 inducers. These drugs should be stopped at least 14 days prior to registration to Step 0. * Current uncontrolled medical conditions that could limit a subject's ability to undertake study therapy * Inflammatory bowel disease with diarrhea as a major component * Key Criteria for Step 1: Subjects must NOT meet any of the following criteria to be enrolled: * Normally active HER2 signaling as determined by the CELsignia test on the tumor tissue * Inconclusive HER2 signaling testing by the CELsignia test on the tumor tissue * Whole-brain radiotherapy in the prior three months * Resting blood pressure higher than systolic of 160 and/or diastolic of 110 mmHg or poorly controlled hypertension, history of labile hypertension, or poor compliance with anti-hypertensive medication * Serious cardiac illness or condition including, but not limited to, clinically significant congestive heart failure, high-risk uncontrolled arrhythmias, unstable angina pectoris requiring medication, or clinically significant valvular heart disease * History of pulmonary embolus or deep vein thrombosis diagnosed within the previous three months * Current uncontrolled medical conditions that could limit a subject's ability to undertake study therapy * Known or suspected leptomeningeal disease * Inflammatory bowel disease with diarrhea as a major component * Chronic and concomitant use of strong or moderate CYP3A4 inhibitors and strong or moderate CYP3A4 inducers. These drugs should be stopped at least 14 days prior to registration to Step 1.
Conditions HER2-positive Advanced Breast Cancer
Phase PHASE3
Enrollment 416
Locations 75 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-09
Study Details Design, interventions, and primary outcomes

About This Study

TQB2930 is a HER2 bispecific antibody drug. This study aims to evaluate the efficacy and safety of TQB2930 combined with investigator's choice of chemotherapy versus trastuzumab combined with investigator's choice of chemotherapy in subjects with HER2-positive advanced breast cancer who have received at least two prior lines of anti-HER2 therapy in the advanced station.

Design

Study type: Interventional Phases: Phase3 Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Drug: TQB2930+ chemotherapy — TQB2930 injection is a HER2 bispecific antibody drug; Chemotherapy: Capecitabine Tablets, Gemcitabine Hydrochloride for Injection, Vinorelbine Tartrate Injection and Eribulin Mesylate Injection are Chemotherapy Drugs.
  • Drug: Trastuzumab+ chemotherapy — Trastuzumab is a HER2-specific targeted drug; Capecitabine Tablets, Gemcitabine Hydrochloride for Injection, Vinorelbine Tartrate Injection and Eribulin Mesylate Injection are Chemotherapy Drugs.

Primary Outcomes

  • Progression-free survival (PFS) (Baseline up to IRC-assessed Disease Progression(PD), approximately 1 years)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE3
Status: Recruiting
Start Date: 2025-07-25
Completion: 2028-12
Eligibility
Age: 18 Years – 75 Years
Sex: ALL
Volunteers: false
Enrollment: 416 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
Contact Information
Study Contact:
Qingyuan Zhang, Doctor
13313612989
ns86298333@163.com
Jinming Yu, Doctor
13806406293
sdyujinming@126.com
Mingliang Zhang, Master
13855269689
19257387@qq.com
The First Affiliated Hospital of Bengbu Medical College
Interventions
  • Drug: TQB2930+ chemotherapy — TQB2930 injection is a HER2 bispecific antibody drug; Chemotherapy: Capecitabine Tablets, Gemcitabine Hydrochloride for Injection, Vinorelbine Tartrate Injection and Eribulin Mesylate Injection are Chemotherapy Drugs.
  • Drug: Trastuzumab+ chemotherapy — Trastuzumab is a HER2-specific targeted drug; Capecitabine Tablets, Gemcitabine Hydrochloride for Injection, Vinorelbine Tartrate Injection and Eribulin Mesylate Injection are Chemotherapy Drugs.
Study Locations (75 sites)
The First Affiliated Hospital of Bengbu Medical College, Bengbu, Anhui 233060 China
Anhui Provincial Hospital( The First Affiliated Hospital of USTC), Hefei, Anhui 230001 China
The Second Affiliated Hospital of Anhui Medical University, Hefei, Anhui 230001 China
The Fifth Medical Center of Chinese People's Liberation Army General Hospital, Beijing, Beijing Municipality 100071 China
Chong Qing University Cancer Hospital, Chongqing, Chongqing Municipality 400030 China
Fuzhou First Generel Hospital Affiliated with Fujian Medical University, Fuzhou, Fujian 350009 China
The First Hospital of Lanzhou University, Lanzhou, Gansu 730000 China
Gansu Cancer Hospital, Lanzhou, Gansu 730050 China
Sun Yat - sen University Cancer Center, Guangzhou, Guangdong 510060 China
Peking University Shenzhen Hospital, Shenzhen, Guangdong 518000 China
Eligibility Criteria
Inclusion Criteria: * Subjects voluntarily participate in this study and sign the informed consent form; * Age: 18-75 years (at time of signing Informed Consent Form (ICF); Eastern Cooperative Oncology Group (ECOG) performance status ≤1; estimated life expectancy \>3 months; * Cytologically or histologically confirmed Human Epidermal Growth Factor Receptor 2 (HER2)-positive recurrent or metastatic breast cancer; * Received ≥2 prior lines of anti-HER2 targeted therapy in the advanced setting; * At least one measurable lesion meeting Response Evaluation Criteria in Solid Tumors, Version 1.1 (RECIST 1.1) criteria (excluding brain lesions); * Willing to receive one of the investigator-selected chemotherapy regimens; * Adequate organ function; * Female subjects of childbearing potential must agree to use effective contraception (e.g., Intrauterine Device (IUD), oral contraceptives, or condoms) during the study and for 6 months after study completion. Exclusion Criteria: * Concurrent Diseases and Medical History: * Other malignancies within 5 years before randomization or concurrent malignancies (except adequately treated non-melanoma skin cancer, in situ cervical cancer, or other cancers with curative treatment and no recurrence for ≥3 years); * Uncontrolled toxicities (\>CTCAE Grade 1) from prior therapies (excluding alopecia); * Major surgery, open biopsy, or significant traumatic injury within 28 days before randomization; * Non-healing wounds or fractures; * Arterial/venous thromboembolic events within 6 months before randomization; * History of drug abuse or psychiatric disorders that may affect compliance; * Poorly controlled hypertension (e.g., Systolic Blood Pressure (SBP) \>160 mmHg despite treatment); * ≥Grade 2 myocardial ischemia/infarction, arrhythmias, or congestive heart failure (New York Heart Association (NYHA)Class ≥II); * Active or uncontrolled severe infections (≥CTCAE Grade 2); * Known chronic hepatitis B; * Active syphilis infection; * Renal failure requiring hemodialysis/peritoneal dialysis; * Immunodeficiency disorders (e.g., Human Immunodeficiency Virus (HIV) ; * Poorly controlled diabetes; * Urine protein ≥++ on dipstick with 24-hour urine protein \>1.0 g; * Epilepsy requiring medication. * Tumor-Related Conditions and Treatments: * Chemotherapy, radiotherapy, or immunotherapy within 4 weeks before randomization (or within 5 half-lives of prior drugs, whichever is shorter); * Chinese herbal medicines with approved antitumor indications (per National Medical Products Administration (NMPA) labeling) within 2 weeks; * Severe Bone Lesions from bone metastases; * Untreated brain metastases, Leptomeningeal metastases, or carcinomatous meningitis; * Prior HER2-targeted therapy-induced Left Ventricular Ejection Fraction (LVEF) decline to \<50% or absolute reduction \>15%; * Uncontrolled or symptomatic Hypertension requiring ongoing bisphosphonates; * Uncontrolled cancer-related pain; * Existed Lymphangitis Carcinomatosa or uncontrolled effusions; * Use of Immunosuppressant or systemic corticosteroids (≥10 mg/day prednisone equivalent) within 2 weeks. * Severe hypersensitivity to monoclonal antibodies; * Participation in other antitumor clinical trials with investigational drugs within 4 weeks before randomization; * Any condition deemed by the investigator to jeopardize subject safety or study completion.
Conditions Cancer, Solid Tumor, Colorectal Cancer, ...
Phase PHASE1
Enrollment 50
Locations 2 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-09
Study Details Design, interventions, and primary outcomes

About This Study

Solid tumors pose significant challenges in current therapeutic approaches. Targeted therapy has emerged as a promising avenue, aiming to enhance treatment efficacy while minimizing adverse effects. This clinical trial focuses on an innovative combination of two targeted inhibitors, Palbociclib and Bevacizumab, for their potential synergistic effects in addressing these challenging malignancies. Moreover, this study incorporates a molecular approach by considering Long Non-Coding RNAs (LncRNAs) as biomarkers. Initiating with a focus on colorectal cancer, the study aims to expand its scope to other solid tumors, including lung, breast, ovarian and other cancers. Palbociclib, a cyclin-dependent kinase 4/6 (CDK4/6) inhibitor, disrupts the cell cycle progression, particularly in cancer cells with specific molecular characteristics. Bevacizumab, a vascular endothelial growth factor (VEGF) inhibitor, targets angiogenesis-a critical process for tumor growth and metastasis. The rationale behind combining these agents lies in their complementary mechanisms of action, potentially leading to enhanced antitumor effects. LncRNAs have shown promise in predicting treatment response and prognosis in various cancers, providing an additional layer of precision to the treatment strategy. By elucidating the molecular basis through LncRNA analysis, the trial aims to tailor the treatment to the specific molecular profile of each patient, ultimately striving for better outcomes and improved survival rates. This novel combination therapy, coupled with a personalized biomarker-driven approach, represents a cutting-edge strategy in the pursuit of more effective and individualized treatment for solid tumors.

Design

Study type: Interventional Phases: Phase1 Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: Single

Interventions / Regimen

  • Genetic: SNP — Diagnostics of patients' carriers or not of the risk allele(s)
  • Drug: Palbociclib 125mg — Palbociclib 125mg/day/os over 21 days every 28 days
  • Drug: Bevacizumab — 10mg/kg every 21 days

Primary Outcomes

  • Assessment of Cancer Progression ([Time Frame: up to 60 months])
  • Identification of Potential Biomarkers ([ Time Frame: Once at the moment of the patient's enrollment in the study])
  • Evaluation of Treatment Response to Palbociclib and Bevacizumab Combination Therapy ([ Time Frame: up to 60 months])
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE1
Status: Recruiting
Start Date: 2023-02-15
Completion: 2027-12
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 50 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Lebanese University
Collaborators: Haykel Hospital
Principal Investigators:
  • Nehman Makdissy, Professor (STUDY_CHAIR) - Lebanese University
Contact Information
Study Contact:
Nehman Makdissy, Professor
71210250
nehman.makdissy@ul.edu.lb
David Wehbe, MD
Wehbehdavid@hotmail.com
Haykel Hospital
Malak Naboulsi, PharmD
malak.naboulsi@gmail.com
Haykel Hospital
Interventions
  • Genetic: SNP — Diagnostics of patients' carriers or not of the risk allele(s)
  • Drug: Palbociclib 125mg — Palbociclib 125mg/day/os over 21 days every 28 days
  • Drug: Bevacizumab — 10mg/kg every 21 days
Study Locations (2 sites)
Haykel Hospital, Tripoli, North Lebanon 961 Lebanon
Lebanese University, Tripoli, North Lebanon 961 Lebanon
Eligibility Criteria
Inclusion Criteria: * Individuals of white ethnicity. * Age between \> 18 * Both males and females. * Diagnosis of selected cancer type (e.g., colorectal cancer, lung cancer, genitourinary cancers, breast cancer). * Cancer stage III/ IV with or without metastasis or lymph node dissemination at the time of enrollment. * Unrelated patients. Exclusion Criteria: * History of hematological cancer types or previous cancers, recurrent or relapse. * Diagnosis of inflammatory bowel diseases. * Pre-existing cardiovascular diseases or coronary artery diseases. * Confirmed treated or untreated autoimmune diseases. * Metabolic disorders, diabetes, or hypertension. * Neurological diseases. * Evidence of cardiac, renal, bone, or cerebral damage. * Presence of more than one type of malignancies. * Active infections or myositis. * Familial polyposis. * Alcohol or smoking habits. * Body mass index (BMI) \>30. * Significant weight loss within the last 2 years. * History of surgeries. * Pregnancy. * Related patients.
Conditions Anatomic Stage III Breast Cancer AJCC v8...
Phase PHASE1, PHASE2
Enrollment 138
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-09
Study Details Design, interventions, and primary outcomes

About This Study

This phase I/II trial tests the safety and tolerability of an experimental personalized vaccine when given by itself and with pembrolizumab in treating patients with solid tumor cancers that have spread to other places in the body (advanced). The experimental vaccine is designed target certain proteins (neoantigens) on individuals' tumor cells. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving the personalized neoantigen peptide-based vaccine with pembrolizumab may be safe and effective in treating patients with advanced solid tumors.

Design

Study type: Interventional Phases: Phase1, Phase2 Allocation: Non Randomized Intervention model: Sequential Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Drug: Cyclophosphamide — Given IV
  • Biological: Neoantigen Peptide Vaccine — Receive personalized neoantigen vaccine SC
  • Biological: Pembrolizumab — Given IV
  • Biological: Sargramostim — Given SC
  • Procedure: Biospecimen Collection — Undergo blood sample collection
  • Procedure: Biopsy — Undergo tissue biopsy
  • Procedure: Computed Tomography — Undergo CT
  • Procedure: Magnetic Resonance Imaging — Undergo MRI

Primary Outcomes

  • Maximally tolerated dose (MTD) (Phase I, Cohort 1, Cohort 2, and Pilot Cohort 5) (Up to 2 years)
  • Dose Limiting Toxicity (DLT) (Phase I, Cohort 1, Cohort 2, and Pilot Cohort 5) (Up to 2 years)
  • Incidence of adverse events (Phase I, Cohort 1, Cohort 2, and Pilot Cohort 5) (Up to 2 years from first vaccine administration)
  • Event free survival (EFS) (Phase II Cohort 3) (Up to 2 years)
  • Disease-free survival (DFS) (Phase II Cohort 4) (Up to 2 years)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE1, PHASE2
Status: Recruiting
Start Date: 2022-03-31
Completion: 2028-03-31
Eligibility
Age: 16 Years and older
Sex: ALL
Volunteers: false
Enrollment: 138 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Mayo Clinic
Principal Investigators:
  • Yanyan Lou, MD, PhD (PRINCIPAL_INVESTIGATOR) - Mayo Clinic
Contact Information
Study Contact:
Clinical Trials Referral Office
855-776-0015
mayocliniccancerstudies@mayo.edu
Clinical Trial Referral Office
855-776-0015
mayocliniccancerstudies@mayo.edu
Mayo Clinic in Florida
Yanyan Lou, MD, PhD
Mayo Clinic in Florida
Interventions
  • Drug: Cyclophosphamide — Given IV
  • Biological: Neoantigen Peptide Vaccine — Receive personalized neoantigen vaccine SC
  • Biological: Pembrolizumab — Given IV
  • Biological: Sargramostim — Given SC
  • Procedure: Biospecimen Collection — Undergo blood sample collection
Study Locations (1 sites)
Mayo Clinic in Florida, Jacksonville, Florida 32224-9980 United States
Eligibility Criteria
Inclusion Criteria COHORT 1 and COHORT 2 are no longer enrolling. PHASE I PRE-REGISTRATION, ALL: * Willing to provide tissue specimens per protocol, or have clinically collected formalin-fixed paraffin-embedded (FFPE) tissue blocks, or available sequencing data available from commercial or research tests * NOTE 1: Includes fresh tissue specimen at pre-registration, or with or clinically collected FFPE tissue blocks for complete exome and transcriptome sequencing. Patients who had tumor sequencing under certain Mayo IRB protocols and neoantigen has been identified or REAL Neo vaccine produced are allowed to proceed to pre-registration and/or registration. * NOTE 2: This criteria will not apply to patients who had sequencing and neoantigen prediction previously completed. * Measurable disease as defined by RECIST (v 1.1) criteria or non-measurable disease * NOTE: Tumor lesions in previously irradiated area are not considered measurable disease * Patients with actionable genomic abnormality including, but not limited to EGFR, ALK, MET, ROS-1, RET, NTRK, KRAS or BRAF must have received and progressed on at least one line of prior FDA-approved targeted therapy * Provide written informed consent. For pediatric patients (age 16-17 years): * Written informed consent from legal guardian(s) and/or child obtained in accordance with local regulations. * Willing to return to enrolling institution for follow-up * Willing to provide blood specimens for research * Negative pregnancy test 7 days prior to pre-registration for persons of childbearing potential. * Willing to employ highly effective method of contraception from pre-registration through 6 months after final vaccine cycle * Willing to receive tetanus vaccination if subject has not had one ≤ 1 year prior to pre-registration * Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) of 0 or 1 * Anticipated life expectancy \> 6 months * Recovered from all toxicities associated with prior treatment to acceptable baseline status (see specified inclusion limits for laboratory toxicity) or National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) v5 Grade 0 or 1, except for toxicities not considered safety risk per treating investigator (e.g., alopecia or vitiligo). * The following lab values obtained ≤ 28 days prior to pre-registration: * Hemoglobin ≥ 9.0 g/dL (Must be ≥ 7 days after most recent transfusion) * Absolute neutrophil count (ANC) ≥ 1500/mm\^3 or ≥ 1.5 X 10\^9/L * Platelet count ≥ 100,000/mm\^3 or ≥ 100 X 10\^9/L (Must be ≥7 days after most recent transfusion) * Total bilirubin ≤ 1.5 x upper limit of normal (ULN) * Aspartate transaminase (AST) and alanine transaminase (ALT) ≤ 3 x ULN or ≤ 5 x ULN with liver metastases * Creatinine ≤ 1.5 x ULN OR calculated creatinine clearance must be ≥ 50 ml/min using Cockcroft-Gault formula * International normalized ratio (INR) or prothrombin time (PT) and activated partial thromboplastin time (aPTT) ≤ 1.5 x ULN unless patient is receiving anticoagulant therapy in which case PT or PTT must be within target range of therapy PHASE I REGISTRATION, ALL: * Successful sequencing and production of REAL-Neo vaccine * Measurable disease as defined by RECIST (v 1.1) criteria or non-measurable disease * NOTE: Tumor lesions in previously irradiated area are not considered measurable disease * ECOG PS 0 or 1 * Anticipated life expectancy \> 6 months * The following lab values obtained ≤ 14 days prior to registration: * Hemoglobin ≥ 9.0 g/dl * ANC ≥ 1500/mm\^3 * Platelet count ≥ 100,000/mm\^3 * Total bilirubin ≤ 1.5 x ULN * ALT and AST ≤ 3 x ULN (≤ 5 x ULN with liver involvement) * PT/INR and aPTT ≤ 1.5 x ULN unless patient is receiving anticoagulant therapy in which case INR or aPTT must be within target range of therapy * Calculated creatinine clearance ≥ 50 ml/min using Cockcroft-Gault formula * Provide written informed consent * Willing to provide blood and tissue specimens for research * Willing to return to enrolling institution for follow-up * Patients with actionable genomic abnormality including, but not limited to EGFR, ALK, MET, ROS-1, RET, NTRK, KRAS or BRAF must have also received and progressed on at least one line of prior FDA-approved targeted therapy * Negative pregnancy test ≤ 14 days prior to registration for persons of childbearing potential only * NOTE: If urine test cannot be confirmed negative, serum pregnancy test will be required * Willing to employ highly effective method of contraception from pre-registration through 6 months after final vaccine cycle * Willing to receive tetanus vaccination if subject has not had one ≤ 1 year prior to pre-registration * Recovered from all toxicities associated with prior treatment to acceptable baseline status or NCI CTCAE v5 Grade of 0 or 1, except for toxicities not considered safety risk per treating investigator (e.g., alopecia or vitiligo) PHASE II PRE-SCREENING COHORT 3 ONLY: * ECOG PS 0 or 1 * Histological confirmation of adenocarcinoma of the breast with estrogen receptor (ER) \< 10%, progesterone receptor (PR) \< 10%, and HER2 negative based on current American Society of Clinical Oncology (ASCO)/College of American Pathologists (CAP) guideline * Stage I-III based on 7th edition of TNM staging system from American Joint Committee on Cancer (AJCC) * Evidence of residual disease ≥ 1 cm after neoadjuvant pembrolizumab-based chemotherapy on imaging for patients who have not had surgery * Willing to proceed with surgery and provide tissue and blood specimens for patients who have not had surgery, willing to provide clinically collected FFPE tissue blocks, or willing to provide available sequencing data available from commercial or research test * Provide written informed consent * Willing to return to enrolling institution for follow-up PHASE II PRE-SCREENING COHORT 4 ONLY: * ECOG PS 0 or 1 * Histological confirmation of lung NSCLC * No actionable EGFR mutations and ALK fusions * Stage II or stage III based on AJCC 8th * Tumor ≥ 2 cm on pre-surgery evaluation imaging (residual disease ≥ 2 cm after neoadjuvant therapy on pre-surgery evaluation imaging in patient who receives neoadjuvant therapy) for patients who have not had surgery. Patients with or without neoadjuvant chemotherapy or immunotherapy are allowed * Provide written informed consent * Willing to proceed with surgery and provide tissue and blood specimens for patients who have not had surgery * Willing to return to enrolling institution for follow-up PHASE II PRE-REGISTRATION COHORT 3 (TNBC) ONLY: * Histologically confirmed residual cancer burden 2 and 3 in surgical specimens PHASE II PRE-REGISTRATION COHORT 4 (NSCLC) ONLY: * Tumor without complete pathologic response is confirmed in pathology * Willing to employ highly effective method of contraception from pre-registration through 6 months after final vaccine cycle * ECOG PS of 0 or 1 * Anticipated life expectancy \> 6 months PHASE II PRE-REGISTRATION PILOT AND COHORT 5: * Provide written informed consent. For pediatric patients (age 16-17 years): * Written informed consent from legal guardian(s) and/or child obtained in accordance with local regulations * Willing to proceed with surgery and provide mandatory tissue specimens or previously collected FFPE tissues for complete exome and transcriptome sequencing or available sequencing data available from commercial or research test * NOTE: Patients who had sequencing under Mayo IRB protocol #13-000942, #14-004094, or #21-007742 and neoantigens have been identified or REAL Neo vaccine produced are allowed to proceed to pre-registration and/or registration * Negative pregnancy test done ≤ 7 days prior to pre-registration for persons of childbearing potential only * NOTE: If the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required * Willing to employ a highly effective method of contraception from the t